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Abstract A retrospective study was conducted to assess
changes in cerebrovascular lesions, as assessed by magnetic
resonance (MR) imaging and angiography in 18 children
with sickle cell disease (SCD) receiving optimised chronic
transfusions for primary stroke prevention (abnormal trans-
cranial Doppler flow, nine patients, median follow-up
14.3 months (range, 7.9–48.9)) or secondary stroke pre-
vention (nine patients, median follow-up 59.6 months
(range, 11.0–127.9)). An experienced neuroradiologist
blinded to patient data reviewed the 41 MR scans
(median/patient, three (2–4)). Standard scores were used
to evaluate parenchymal and vascular abnormalities at
baseline and last follow-up. Within-patient score changes
evaluated using Wilcoxon’s paired rank test indicated lesion
progression in the secondary-prevention group (p=0.027).
Optimised transfusion therapy does not prevent progression
of cerebral vasculopathy in SCD children with a history of
stroke.
Keywords Sickle cell disease . Stroke . Transfusion .
Brain imaging
Cerebral vasculopathy is not only among the most severe
complications of sickle cell disease (SCD) in children, but
also extremely common, with an overall prevalence by
magnetic resonance imaging (MRI) of up to 55% [1].
Clinical evidence of stroke occurs by 20 years of age in
11% of patients with SCD [2] and the incidence of stroke is
1.02% per year between 2 and 5 years of age. In addition to
stroke, cerebral vasculopathy can cause cognitive impair-
ments that adversely affect educational outcomes [3–5].
Transfusion therapy has been found effective for primary
and secondary stroke prevention in patients with SCD. In
the randomised STOP study of children whose transcranial
Doppler (TCD) results indicated a high risk of stroke [6],
regular blood transfusions reduced the risk of stroke by
90%. Similarly, transfusion therapy was effective in
reducing the risk of recurrent stroke, although transient
neurological events were not decreased [7, 8]. Stopping a
regular transfusion regimen has been associated with a high
rate of stroke recurrence [9]. In children whose TCD results
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returned to normal after regular transfusions for at least
30 months, stopping the transfusions was associated with
recurrence of abnormal blood-flow velocities and with stroke
[10]. Despite the convincing evidence that transfusion is
beneficial in children at high risk for neurological compli-
cations, no data are available on long-term magnetic
resonance imaging or angiography (MRA) in children with
SCD who receive regular transfusions. Longitudinal studies
involving serial TCD studies suggest that transfusion therapy
may markedly reduce both blood-flow velocity in the middle
cerebral arteries and red-cell sickling [11]. However,
conventional angiography studies have shown mild progres-
sion of vascular lesions over time, despite an initial decrease
in vessel irregularity [12], suggesting that transfusions may
fail to stabilise or improve the vascular lesions.
Our objective was to assess changes in MRI and MRA
evidence of cerebrovascular disease over time in children
with SCD receiving optimised chronic transfusion therapy.
Materials and methods
Patients
We reviewed the records of all consecutive children with
homozygous SCD who received chronic transfusion
therapy for primary or secondary stroke prevention at the
Necker Enfants Malades Hospital, Paris, France, from June
1994 to June 2006. We identified 18 patients, nine boys and
nine girls. Among them, nine were started on primary
prevention after TCD screening showed abnormal blood-
flow velocities (time-averaged mean of the maximum
velocity≥200 cm per second) and nine were put on
secondary prevention after sustaining a first stroke. These
last patients had experienced a cerebrovascular accident
before the implementation of annual TCD screening as
standard care and have subsequently the longest follow-up.
Chronic transfusion therapy was initiated within 1 month
after the stroke or abnormal TCD screen. Patients received
either transfusions or exchange transfusions according to
the haemoglobin level at admission. We recorded the
following data: age at the first stroke or abnormal TCD
screen, time of transfusion therapy initiation and results of
monthly complete blood cell counts and haemoglobin S
(HbS) determinations.
Brain imaging
MRI and MRA were performed at 1- to 2-year intervals in
all patients. Because these investigations were part of
standard care and the study design was retrospective,
informed consent from the patients and families was not
required.
Before 1998, there was no standard protocol, but MR
evaluation included at least T1- and T2-weighted sequences
and 3D time-of-flight MRA images. After 1998, MR
evaluation routinely included 5-mm-thick T1- and
T2-weighted images and 4-mm-thick FLAIR images, as
well as 3D time-of-flight 1.2-mm-thick MRA images. All
images were reviewed twice by an experienced neuroradiol-
ogist (LH-P), who was unaware of patient identity, history
and date of imaging. Image quality was scored from 1 to 3 (1,
unacceptable movement artefact or missing sequence;
2, minor movement artefact and 3, high-quality images).
We excluded the six investigations that received a score of 1.
Scoring systems adapted from Steen [1] were used to evaluate
parenchymal abnormalities (lacunae, leucoencephalopathy,
cerebral atrophy and encephalomalacia) and vascular abnor-
malities (arterial tortuosity, stenosis, occlusion and moya-
moya); scores could range from 0 to 16 (Table 1).
Statistical analysis
Quantitative variables were expressed as median (range).
MRI scores, MRA scores and total MR scores at baseline
and at last follow-up were compared in each patient using
Wilcoxon paired rank tests.
Results
Median age at first stroke (n=9) was 7.6 years (3.0–10.8)
and median age at first abnormal TCD was 6.5 years
(4.0–12.8). Median follow-up was 59.6 months (11.0–
127.9) in the stroke group and 14.3 months (7.9–48.9)
in the abnormal-TCD group. Mean pre-transfusion HbS
percentage was 30.8±4.7 in the stroke group and 33.3±
9.8 in the abnormal-TCD group. Corresponding mean
post-transfusion HbS percentages were 21.4±2.9 and
22.9±6.5, respectively.
The 18 patients had 41 MR evaluations included in the
analysis (Table 2). The median number of MR evaluations
per patient was 3 (2–4). In the stroke group, the median
total score (MRI+MRA) was 10 [2–22] at baseline and 12
[3–26] at last follow-up (p=0.027). Thus, progression of
the MR abnormalities occurred despite adequate transfusion
therapy in patients with a history of a single stroke episode.
In the abnormal-TCD group, the median total score was 0
(0–7) at baseline and 0 (0–10) at last follow-up.
Discussion
Cerebrovascular lesions as assessed by MR worsened in
children with SCD who had a history of stroke, despite
chronic transfusion therapy that kept the HbS percentage
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within the range usually considered protective [7]. In the
abnormal-TCD group, MR evaluation showed no change,
but the follow-up was too short to draw conclusions from
this finding. Although age was comparable in the two
groups, the total MR score at baseline was lower in the
abnormal-TCD group, in keeping with the hypothesis that
increased cerebral blood-flow velocity antedates the devel-
opment of MR abnormalities.
The worsening MR findings in the stroke subgroup were
clinically silent in eight of the nine patients; the remaining
patient experienced a second stroke episode. Stroke
recurrence has been reported previously in children receiv-
ing monthly transfusions for SCD [7, 8] however, in these
previous studies, HbS levels were greater than 30% in most
of the patients and were most likely to be high among
patients who experienced recurrent stroke or transient
ischemic attacks. The rate of recurrent stroke was 1.9 per
100 patient-years in a retrospective study where most
patients had less than 30% HbS [8]. It was only 1.15 per
100 patient-years in our study, suggesting that 30% may be
a good HbS target level. However, despite the optimal
transfusion regimen used in our study, cerebrovascular
lesions worsened in the patients who had a history of
stroke. Although the long-term consequences of this finding
are unclear, children with progressive cerebrovascular
disease may experience cognitive impairments and an
increased risk of moya-moya disease.
The reasons for the inability of regular transfusions to
halt the progression of cerebrovascular disease in children
with SCD and a history of stroke deserve discussion.
Factors that may be relevant include the genetic makeup
and lesion severity at treatment onset. Conceivably,
specific genetic influences may result in progressive
vascular lesions that fail to respond to transfusion therapy.
In keeping with this possibility, a small minority of
children in the STOP study had persistent increases in
cerebral blood-flow velocities despite transfusion therapy
Table 1 Method for scoring abnormalities found by magnetic
resonance imaging and angiography, adapted from Steen et al. [1]
Lacunae Leuco-
encephalopathy
Atrophy Encephalomalacia
0: absence 0: absence 0: absence 0: absence
1: <1 cm
unilateral
1: ≤3 cm
unilateral
1: ≤1 unilateral
territory
1: ≤1 unilateral
territory
2: >1 cm
unilateral
2: >3 cm
unilateral
2 >1 unilateral
territory
2 >1 unilateral
territory
3: <1 cm
bilateral
3: ≤3 cm
bilateral
3 ≤1 bilateral
territory
3 ≤1 bilateral
territory
Tortuosity Stenosis/occlusion
of right and left
MCA, ACA, ICA
Moya moya
0: absence 0: absence 0: absence
1: unilateral 1: <50% 1: unilateral
2: bilateral 2: ≥50% 2: bilateral
3: 100%
MCA middle cerebral artery, ACA anterior cerebral artery, ICA internal
carotid artery
Table 2 Clinical data and scores of patients
Patient Date of
birth
Inclusion
criteria
Date transfusion
program started
Date of first
MR
Quality
score
Initial
score
Date of
last MR
Quality
score
Final
score
1 15/02/00 Stroke 1/09/05 15/09/05 3 10 15/08/06 2 10
2 26/06/86 Stroke 1/01/1994 15/02/94 3 14 17/01/03 3 23
3 31/08/90 Stroke 1/07/96 15/06/98 3 13 6/06/06 3 12
4 23/06/88 Stroke 1/05/95 1/03/96 2 9 1/03/03 3 10
5 14/06/00 Stroke 1/11/03 1/01/05 3 4 11/07/06 3 5
6a 13/08/92 Stroke 1/02/96 1/08/96 2 9 6/04/06 3 23
7 16/01/91 Stroke 1/02/01 26/01/01 3 22 4/01/06 3 26
8 30/03/90 Stroke 1/10/98 1/01/99 3 19 30/05/06 3 25
9 18/09/97 Stroke 1/02/02 16/07/02 2 2 1/12/04 3 3
10 4/07/97 TCD 1/05/05 8/05/05 3 0 18/07/06 3 0
11 23/12/98 TCD 1/12/04 1/01/05 3 1 11/17/2006 3 1
12 23/09/93 TCD 1/01/04 1/02/04 3 6 28/06/06 3 8
13 19/08/01 TCD 1/06/05 1/09/05 3 0 1/05/06 3 0
14 16/11/99 TCD 1/08/05 15/08/05 3 7 11/08/06 3 10
15 5/02/99 TCD 1/01/05 1/08/05 3 0 7/08/06 3 0
16 6/05/97 TCD 1/06/05 24/06/05 3 0 3/08/06 3 0
17 11/11/97 TCD 1/11/02 1/08/02 2 0 30/08/06 2 0
18 20/09/91 TCD 1/04/04 19/07/04 2 0 12/07/06 3 1
a Patient 6 experienced recurrence of overt stroke despite chronic exchange transfusion program
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[6]. Another possibility is that the vascular lesions may
become refractory to treatment once they have crossed a
severity threshold. The absence of disease progression in
the abnormal-TCD group may be related to the short
follow-up.
Our study has limitations inherent to the retrospective
design. Advances in imaging techniques in recent years
have increased the ability to detect lesions [1]. In our study,
however, the same imaging protocol was used from 1998 to
2006, so that a role for technical changes in the worsening
of MR findings is unlikely. In addition, the quality score
filter strongly reduced the risk of spurious interpretation
of low quality images. Both reproducibility and accuracy of
imaging criteria are critical issues. We are unaware of other
longitudinal studies using the Steen et al. scoring system. In
this study, all scans were reviewed twice by an experienced
(>15 years) pediatric neuroradiologist blinded to any
clinical data. After complete analysis of randomly ordered
scans of all mixed patients, the longitudinal sequence of
each patient was reviewed allowing a retrospective deter-
mination of the accuracy of the previous readings. This
internal check proved a high degree of reproducibility as
only in two cases did discrepancies lead to a third
determination. In the original Steen et al. study, the inter
observer variability was deemed low and all discrepant
cases could be solved by consensus. We used a validated
score1 for within-patient comparisons over time. However,
the score items do not reflect a single pathophysiological
process. For this reason, and because the number of patients
was limited, a separate analysis of microvessel and macro-
vessel damage was not feasible. Such an analysis would
help to identify the mechanisms that lead to cerebrovascular
disease progression.
In conclusion, our findings do not challenge the
usefulness of chronic transfusion in children with SCD
and a history of stroke or abnormal TCD. They establish
that, in patients with a history of stroke, SCD-related
cerebrovascular damage continues to progress despite
chronic transfusion keeping HbS levels below 30%. The
long-term consequences of cerebrovascular disease pro-
gression are unclear. Little is known about changes in brain
parenchyma damage after haematopoietic stem cell trans-
plantation for severe SCD [13]. Therefore, we do not know
whether early transplantation would be more effective in
preserving a normal neurodevelopmental pattern than
chronic transfusion in at-risk SCD children. Knowledge of
the mechanisms involved in SCD-related brain damage
would help to determine the best treatment strategy for
preventing this devastating complication.
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